Drug maker Wockhardt is said to have put its two active pharmaceutical ingredient (API) facilities for sale, CNBC-TV18 reported on Tuesday.
The company is said to be looking at raising Rs.150-200 crore from the sales of these facilities, CNBC-TV18 report said quoting sources.
Wockhardt’s API sites were put to sale at distressed valuations.
Wockhardt has an API plant in Ankleshwar, Gujarat. The plant was under import ban by US FDA from August 2016.
Wockhardt denied any divestment of its API sites.
Wockhardt has got shareholder approval to raise up to Rs.1000 crore through sale of its shares.
Wockhardt has three research centres and 12 manufacturing plants, with businesses ranging from the making and marketing of pharmaceuticals, active pharmaceutical ingredients and vaccines.
Shares of Wockhardt dropped 1.15 percent to close at Rs.598.10 on BSE, the benchmark Sensex declined 0.04 percent to end at 31,209.79 points.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
